Close

Nymox Pharma (NYMX) Reports No Top-Line Statistical Significance in NX-1207 Phase 3 Trial

April 1, 2015 10:15 AM EDT Send to a Friend
Nymox Pharmaceutical Corporation (Nasdaq: NYMX) announced today that the Company is undertaking further analyses of its pivotal U.S. Phase 3 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login